Search the Newsreel

Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion

Tempus AI has announced its acquisition of Personalis, a cancer-monitoring firm, for $1.5 billion in an all-stock deal. The acquisition focuses on Personalis' NeXT Personal test, which uses minimal residual disease technology to detect circulating tumor DNA, a market estimated to be worth $20 …

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Tempus AI, Inc. is set to acquire Personalis, Inc. for $1.5 billion, integrating Personalis' molecular residual disease (MRD) technology into Tempus' AI-enabled precision oncology platform. This acquisition aims to enhance cancer monitoring, biomarker discovery, and personalized cancer care by combining Personalis' industry-leading MRD tests …

Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink

Tempus AI, a healthcare technology company, is acquiring cancer testing company Personalis for $1.5 billion. This acquisition led to a significant drop in the stock prices of both companies on Monday. Tempus AI's shares are already down 18% this year.

Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

Tempus AI (TEM) announced its intention to acquire cancer diagnostics company Personalis (PSNL) for $1.5 billion, leading to a decline in shares for both medtech companies. This acquisition follows earlier rumors of interest from Merck and potentially Tempus AI in Personalis, which develops a …

Tempus AI Announces Merger Agreement to Acquire Personalis

Tempus AI, Inc. has announced a definitive merger agreement to acquire genomics company Personalis, Inc. in a two-step merger. The deal, approved by both boards, will involve Personalis shareholders receiving Tempus Class A stock with an option for cash consideration. The acquisition aims to …

Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis

Latham & Watkins LLP advised Tempus AI on its US$1.5 billion acquisition of Personalis, Inc. This acquisition will expand Tempus AI's capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis to monitoring. The Latham & Watkins team was …

M&A: Tempus AI to Acquire Personalis for $1.5B to Expand Precision Oncology and MRD Monitoring

Tempus AI, Inc. is set to acquire Personalis, Inc. for $1.5 billion, integrating Personalis' NeXT Personal® tumor-informed minimal residual disease (MRD) liquid biopsy test into Tempus' AI-enabled clinical data engine. This acquisition targets a $20 billion market and aims to transform cancer patient monitoring …

Tempus to Buy Cancer-Tech Firm Personalis for $1.7 Billion

Tempus AI Inc., an artificial intelligence company focused on disease prevention and treatment, has announced its agreement to acquire Personalis Inc., a cancer-testing company. The deal values Personalis at an equity valuation of $1.7 billion, with Tempus paying its shareholders $16.25 per share, totaling …

Tempus to buy cancer test maker Personalis for $1.5 billion

Tempus AI announced its acquisition of Personalis for approximately $1.5 billion, enhancing its oncology portfolio with Personalis' NeXT personal cancer test. The deal, primarily stock-based, led to a drop in shares for both companies due to investor skepticism regarding Tempus' potential upside. The acquisition …

Tempus to buy cancer-tech firm Personalis for $1.7B

Tempus, a company specializing in cancer technology, has announced its intention to acquire Personalis for $1.7 billion. This acquisition is expected to expand Tempus's capabilities in the health care sector. The deal was reported by Bloomberg.

Q4 2025 Personalis Inc Earnings Call Transcript

Personalis Inc. (PSNL) achieved significant clinical growth in Q4 2025, with a 329% year-over-year increase in clinical tests delivered and secured two Medicare coverage decisions for breast and lung cancer, validating their MRD technology. Despite a planned decline in legacy contract revenue and compressed …

Personalis draws takeover interest from Merck (PSNL:NASDAQ)

Personalis (PSNL) shares surged in premarket trading after reports indicated the company is exploring a potential sale. Merck (MRK) and two other bidders have reportedly expressed takeover interest in the cancer test maker. This news suggests a significant acquisition opportunity in the biotech sector.

Personalis moves off low after blog claims company exploring possible sale

Personalis (PSNL) saw its stock move off its low after a blog claimed the company is exploring a possible sale. This news follows recent analyst price target increases and expanded coverage for their NeXT Personal test, including UKCA marking, EU CE-IVD mark, and Medicare …

Why Is PSNL Stock Up 5% After-Hours?

Shares of Personalis (PSNL) rose 5% after-hours following rumors that the precision oncology company is exploring strategic options, including a potential sale, due to takeover interest from Merck & Co. (MRK) and other parties. Personalis has hired investment banks and a law firm to …

Personalis attracting takeover interest, Street Insider says

Personalis (PSNL), a precision oncology company, is reportedly attracting takeover interest from Merck (MRK) and at least two other suitors. The company has hired bankers from Centerview and TD Securities, along with legal counsel from Cooley, to evaluate a potential sale. This information comes …

Form 4 Personalis Inc For: 15 July By Investing.com

This article announced a Form 4 filing for Personalis Inc. (PSNL) on July 15th, 2026, noting that the stock was up 5.06% at the time of publication. The brief piece serves as a notice of the regulatory filing.

[144] Personalis, Inc. SEC Filing

This article details a Form 144 SEC filing by Personalis, Inc. (PSNL), indicating a proposed sale of 100,000 shares of common stock with an aggregate market value of $1,503,000. The shares were acquired through the exercise of stock options on July 15, 2026, and …

Personalis president and CMO Richard Chen sells $1.5m in stock

Richard Chen, President and Chief Medical Officer of Personalis, Inc., sold 100,000 shares of company stock for $1.515 million after exercising options. The transaction was executed under a Rule 10b5-1 trading plan. The sale occurred as PSNL trades near its 52-week high, though InvestingPro …

PSNL Forecast — Price Target — Prediction for 2027

Personalis Inc. (PSNL) Q1 2026 Earnings: Wider-than-Expected Loss but Stock Surges Over 10% - Tech Earnings Analysis

Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating (NASDAQ:PSNL)

PSNL - Personalis Inc Stock Price and Quote

Personalis Q1 Earnings Call Highlights

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

Personalis Stock Pre-Market (-5.3%): FY26 Guidance Overshadows Q4 EPS Beat

Personalis (PSNL) Faces Persistent Losses and High Valuation as Revenue Growth Outpaces Market

Personalis Reports Mixed Q2: Clinical Tests Soar 59% While Revenue Falls 24% Amid Strategic Shift